行情

ATRS

ATRS

安塔尔制药
NASDAQ

实时行情|Nasdaq Last Sale

3.270
-0.080
-2.39%
盘后: 3.270 0 0.00% 16:31 01/21 EST
开盘
3.320
昨收
3.350
最高
3.377
最低
3.270
成交量
79.69万
成交额
--
52周最高
5.07
52周最低
3.110
市值
5.56亿
市盈率(TTM)
8.69
分时
5日
1月
3月
1年
5年
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
The 
Benzinga · 4天前
Antares Pharma's ATRS-1902 gets US FDA fast track status for adrenal crisis rescue
Antares Pharma's (ATRS -2.4%) hydrocortisone rescue pen ATRS-1902 received the U.S. Food and Drug Administration's fast track designation for adrenal crisis rescue. The company said the development program for ATRS-1902 supports
Seekingalpha · 4天前
BRIEF-Antares Pharma Receives FDA Fast Track Designation For ATRS-1902 For Adrenal Crisis Rescue
reuters.com · 4天前
Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 11% over the...
Simply Wall St. · 01/13 09:46
BRIEF-Antares Pharma Appoints Claude Richardson As Senior Vice President Of Human Resources
reuters.com · 01/12 13:54
Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will...
GlobeNewswire · 01/12 13:30
Antares Pharma reports positive results from Phase I ATRS-1902 study for adrenal crisis
Antares Pharma (NASDAQ:ATRS) announces positive results from a Phase I study for ATRS-1902 for adrenal crisis. Acute adrenal crisis is a life-threatening state caused by insufficient levels of cortisol, which
Seekingalpha · 01/11 14:04
Antares Pharma Announces Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue; Co. Reports 'The results of the Phase I cross-over study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile to Solu-Cortef'
Antares Pharma, Inc. (NASDAQ:ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.
Benzinga · 01/11 12:34
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ATRS最新的财务预测,通过ATRS每股收益,每股净资产,每股现金流等数据分析安塔尔制药近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ATRS价格均价为6.20,最高价位7.00,最低价为5.00。
最高7.00
均价6.20
最低5.00
现价3.270
EPS
实际EPS
预期EPS
0.010.020.030.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 234
机构持股: 9,336.11万
持股比例: 54.90%
总股本: 1.70亿
类型机构数股数
增持
69
437.07万
建仓
21
186.78万
减持
42
419.92万
平仓
19
141.25万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
-0.93%
医疗设备和用品
-1.50%
高管信息
Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Executive Vice President
Peter Richardson
Director
Carmen Volkart
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
暂无数据
ATRS 简况
Antares Pharma Inc(Antares)是一家专业制药公司。该公司专注于医药产品和技术的开发和商业化。该公司使用其药物输送系统为自己或与合作伙伴开发、制造和商业化治疗产品。该公司产品包括XYOSTED、NOCDURNA、肾上腺素注射液USP、舒马普坦注射液USP、Makena和Teriparatide注射液。其XYOSTED注射产品用于成年男性皮下注射睾酮替代疗法(TRT),以治疗与内源性睾酮缺乏或缺乏相关的疾病。NOCDURNA用于治疗每晚至少两次排尿的成人夜间多尿(NP)引起的夜尿症。其肾上腺素注射液USP产品适用于严重过敏反应的紧急治疗,包括成人和某些儿科患者危及生命(过敏反应)的反应。

微牛提供Antares Pharma Inc(NASDAQ-ATRS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATRS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATRS股票基本功能。